MCD Global Health, Malabo, Equatorial Guinea.
MCD Global Health, Silver Spring, MD, USA.
Malar J. 2024 Aug 13;23(1):244. doi: 10.1186/s12936-024-05057-z.
Adherence to anti-malarial treatment regimens is an important aspect of understanding and improving the impact of malaria case management. However, both adherence to artemisinin-based combination therapy (ACT) and the factors driving it vary widely. While many other evaluation activities have been conducted on Bioko Island, until now adherence to anti-malarial treatments, and in particular ACT has not been evaluated.
The implementation of a malaria indicator survey (MIS) conducted on Bioko in 2023 was leveraged to evaluate adherence to ACT provided to individuals testing positive following the survey. A follow-up team visited the targeted households, physically observed treatment blisters where possible, and provided messaging to household members on the importance of adhering to the treatment guidelines to household members. The team used survey data from the targeted households to make messaging as relevant to the household's particular context as possible.
Overall ACT adherence on Bioko Island was low, around 50%, and this varied demographically and geographically. Some of the highest transmission areas had exceptionally low adherence, but no systematic relationship between proper adherence and Plasmodium falciparum prevalence was detected. Estimates of adherence from follow-up visits were much lower than survey-based estimates in the same households (52.5% versus 87.1%), suggesting that lack of proper adherence may be a much larger issue on Bioko Island than previously thought.
Representative surveys can be easily adapted to provide empirical estimates of adherence to anti-malarial treatments, complementary to survey-based and health facility-based estimates. The large discrepancy between adherence as measured in this study and survey-based estimates on Bioko Island suggests a health facility-based study to quantify adherence among the population receiving treatment for symptomatic malaria may be necessary.
抗疟治疗方案的依从性是了解和改善疟疾病例管理影响的一个重要方面。然而,青蒿素为基础的联合疗法(ACT)的依从性及其驱动因素差异很大。虽然在比奥科岛已经进行了许多其他评估活动,但到目前为止,还没有评估过抗疟药物的依从性,特别是 ACT 的依从性。
利用 2023 年在比奥科岛实施的疟疾指标调查(MIS),评估在调查后检测呈阳性的个体接受的 ACT 依从性。一个随访小组访问了目标家庭,在可能的情况下观察治疗泡罩,并向家庭成员传达了遵守治疗指南的重要性。该小组利用目标家庭的调查数据,使信息传递尽可能与家庭的特定情况相关。
比奥科岛的 ACT 总体依从率较低,约为 50%,且在人口统计学和地理上存在差异。一些疟疾传播率较高的地区的依从率极低,但未发现适当的依从性与恶性疟原虫流行率之间存在系统关系。随访访问中的依从性估计值远低于同一家庭的调查估计值(52.5%对 87.1%),这表明在比奥科岛,缺乏适当的依从性可能是一个比以前认为的更大的问题。
有代表性的调查可以很容易地适应,提供抗疟治疗依从性的实证估计,与基于调查和基于卫生机构的估计互补。本研究中测量的依从性与比奥科岛基于调查的估计值之间存在很大差异,这表明可能有必要进行一项基于卫生机构的研究,以量化接受症状性疟疾治疗的人群中的依从性。